Navigation Links
Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data

artis.com/">http://www.novartis.com.
References
[1]. Izzo, J et al. A randomized double-blind, multi-center study to evulate the efficacy of the combination of amlodipine and valsartan in hypertensive patients uncontrolled on previous monotherapy. ASH, 2007
[2]. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
[3]. Diovan Web site. http://www.diovan.com/info/about/about_diovan.jsp. Accessed November 28, 2006.
[5]. World Heart Federation. http://www.worldheart.org/mission-myths-facts.php. Accessed May 8th 2007.
[6]. Chobanian et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42: 12006 - 1251
[7]. Kearney et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223
* Norvasc is a registered trademark of Pfizer Inc.
<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/19/2014)... 2014   Lincor Inc. today announced ... to New Jersey -based healthcare ... Health will deploy Lincor,s PatientLINC technology across its ... and Hoboken University Medical Center. Lincor,s ... solutions to help hospitals reach new levels of ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder ... present a scientific poster describing an innovative diagnostic procedure ... 2014: Shedding New Light on Disease (SPEC) conference in ... Dr. Treado,s poster entitled, "Development of in vitro Diagnostics ... will be discussed during the conference poster session on ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... Claron Technology makes the PROFIT 200 list for ... developer Claron Technology, headquartered in Toronto, has been included ... Fastest-Growing Companies by PROFIT Magazine. Ranking Canada,s Fastest-Growing Companies ... country,s most successful growth companies. Published in the Summer ...
... a medical technology company developing a platform of endoscopically ... obesity and type 2 diabetes, announced today the completion ... led by Broadline Capital, a global private equity investment ... issued and pending patents, will use the funding to ...
Cached Medicine Technology:Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year 2EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital 2
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
... to cover the American Stroke Associations International Stroke Conference ... Ernest N. Morial Convention Center in New Orleans, La. ... world of medical scientists and physicians engaged in research ... death in the United States. Nearly 4,000 attendees ...
... 20, 2008 New data revealing decreasing trends in cancer ... cancer deaths in particular, highlight the remarkable benefits of ... these tests is unrealized for many Americans according to ... Racial minorities, uninsured Americans and even Medicare patients who ...
... Feb. 19 The Ensign,Group, Inc. (Nasdaq: ... the Ensign(TM) group of,skilled nursing, rehabilitative care ... Waverly Park skilled nursing facility in,Tucson, Arizona ... Facility,Program established by the Centers for Medicare ...
... November 5, 2007, under increasing,government pressure, Bayer Pharmaceuticals Corporation ... Trasylol after a Canadian clinical study,found the drug could ... other drugs.,The Food and Drug Administration asked the company ... during heart bypass surgery,pending detailed review of preliminary results ...
... findings show that a specialized virus with the ability to ... brains of mice and eliminate them. Healthy brain tissue remained ... The Journal of Neuroscience . With more research, the technique ... cancer in humans. , Most importantly, this study finds that ...
... Accenx Technologies, Inc., a,leading company in electronic ... solutions, announced today the launch of their,new Physician,s ... their,clients, such as large health systems, hospitals, and ... outreach programs, and connect,physician practices to RyTRAK HIE ...
Cached Medicine News:Health News:US cancer deaths down but far too few Americans screened for colon cancer 2Health News:US cancer deaths down but far too few Americans screened for colon cancer 3Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 2Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 3Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 2Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 3Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 4Health News:Tumor-killing virus selectively targets diseased brain cells 2Health News:New Accenx Physician's Relations Department! Now At Your Service 2
... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
Inquire...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
Medicine Products: